US Pharma Tariff 2026: Decoding the 100% Patented Drug Levy and the Generic Exemption

The US administration has introduced a drastic trade measure targeting pharmaceutical imports under Section 232 of the Trade Expansion Act of 1962. A 100 percent tariff has been imposed on patented pharmaceutical products and their ingredients, as per the White House factsheet issued on April 2, 2026.

The rollout timeline provides 120 days for large firms and 180 days for smaller companies to comply.

This marks a major escalation in US efforts to reduce dependence on imported high-value medicines.

Differential pharma tariff structure across trade partners

The tariff framework adopts a calibrated approach based on trade relationships:

• Imports from the European Union (EU), Japan, South Korea, Switzerland, and Liechtenstein are subject to a 15 percent tariff.
• The United Kingdom benefits from a preferential (lower) tariff regime, linked to an ongoing bilateral pharmaceutical arrangement.

This differentiated structure reflects broader trade and strategic alignments.

Exemptions: Generic drugs and critical therapies

A key feature of the policy is the temporary exclusion of generics, which has direct implications for India:

Generic medicines, biosimilars, and related inputs are currently exempt from tariffs. This exemption extends to supplies for the strategic active pharmaceutical ingredients (API) reserve.

However, the US government has indicated a review within one year, leaving open the possibility of future tariff inclusion.

Additionally, specialty drugs, such as orphan drugs and animal health products, are exempt if deemed essential or sourced from partner countries.

Incentives for domestic pharma products manufacturing and price alignment

The policy combines tariff barriers with incentives to encourage localization and pricing discipline:

• Companies entering into Most Favored Nation (MFN) pricing agreements with US authorities, along with onshoring commitments, will receive zero-tariff treatment until January 20, 2029.
• Firms that only commit to domestic manufacturing (onshoring) will face a reduced tariff of 20 percent.

Regulatory pathways for these arrangements will be administered by the Department of Commerce and the Department of Health and Human Services (HHS).

Strategic rationale: Reducing import dependence

The tariff action follows a national security review that found that pharmaceutical import volumes and sourcing patterns pose risks to the US national security.

It must be noted that the US remains heavily reliant on foreign manufacturing.

Supporting data highlights structural vulnerabilities:

• Around 53 percent of patented drugs consumed in the US are manufactured abroad.
• Only 15 percent of APIs are produced domestically by volume.

Implications for India’s pharmaceutical sector

The policy has asymmetric implications for India, given its export profile. 

Source: Department of Commerce, Ministry of Commerce and Industry, GoI.

*India’s export data for FY 2025-26 is currently available up to February. The complete dataset is expected to be released in the coming weeks.

In FY 2024-25, India exported around US$9.7 billion worth of pharmaceutical products to the US, largely driven by generic drugs.

Leading Indian companies such as Dr. Reddy’s Laboratories, Lupin, Sun Pharma, Glenmark Pharmaceuticals, and Zydus Lifesciences have significant exposure to the US market.

Indian medicines are exported to over 190 countries, with about 50 percent directed to regulated markets.

ALSO READ: Ozempic Generics in India 2026: GLP-1 Drug Manufacturing Race

Near-term impact

• The exemption for generics shields India’s core export segment, limiting immediate disruption.
• Indian firms remain competitive suppliers of affordable medicines in the US healthcare system.

Medium-term risks

Find Business Support

How we can help reduce risk and improve operations in the pharmaceuticals industry

• The one-year review clause introduces uncertainty, as generics could be brought under tariff measures later.
• Increased US focus on domestic API and drug manufacturing could gradually reduce import dependence, affecting Indian exports.

Strategic considerations for India

Indian drug manufacturers and exporters have the opportunity to move up the value chain into complex generics and specialty drugs.

Domestic players need to strengthen API self-sufficiency and cost competitiveness.

There is potential to leverage pricing advantages and supply reliability in ongoing trade discussions.

Alignment with pharma products trade and industrial policy

The tariff move is part of a broader industrial strategy:

• Earlier executive actions (2025) focused on boosting domestic drug manufacturing and building API reserves.
• Parallel Section 232 investigations in sectors such as medical devices and PPE indicate a wider push to secure critical supply chains.

Trade agreements with key partners, including the EU, Japan, South Korea, Switzerland, Liechtenstein, and the UK, are being aligned with these pharmaceutical policy objectives.

Compliance and enforcement framework

To ensure effectiveness, the policy includes:

• External audit mechanisms
• Authority for retrospective and future tariff adjustments in cases of non-compliance

This reflects a shift toward stricter enforcement in strategic sectors.

India’s generic drug manufacturing and export strength

India’s pharmaceutical sector is one of the leading generic drug manufacturing regions, which underpins both its global competitiveness and export performance.

As per the central government, India accounts for approximately 20 percent of global generic medicine supply, producing nearly 60,000 generic brands across multiple therapeutic segments.

Export orientation of generics

In terms of exports, a sizeable portion of India’s pharmaceutical exports is driven by generic formulations, especially to highly regulated markets like the US and Europe.

Find Business Support

Want to know more about investing in India’s pharmaceutical industry? Contact our experts

India’s pharmaceuticals industry ranks 3rd globally by volume and 11th by value. It comprises over 3,000 companies and 10,500 manufacturing facilities. The domestic market, currently valued at US$60 billion, is projected to reach US$130 billion by 2030.

India also has the highest number of USFDA-approved manufacturing plants outside the US, reinforcing international trust in its regulatory and production

Conclusion

The US tariff regime on pharmaceuticals represents a targeted industrial policy intervention, penalizing patented drug imports while temporarily safeguarding generics. For India, the immediate impact is limited due to the exemption of generics, but long-term risks persist as the US pushes for supply chain localization.

The evolving policy landscape underscores the need for Indian pharmaceutical companies to diversify markets, enhance manufacturing depth, and prepare for potential trade disruptions in their largest export destination.

• Previous Article India’s EMI Scheme 2026-2028: New Deferred Customs Duty Facility for Eligible Manufacturer Importers
• Next Article